TY - JOUR
T1 - Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018
T2 - A nationwide Danish study
AU - Ekmann-Gade, Anne Weng
AU - Høgdall, Claus Kim
AU - Seibæk, Lene
AU - Noer, Mette Calundann
AU - Fagö-Olsen, Carsten Lindberg
AU - Schnack, Tine Henrichsen
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2022
Y1 - 2022
N2 - Objective: To examine clinical trends in Denmark for younger and older epithelial ovarian cancer (EOC) patients, focusing on incidence, treatment, and survival changes. Methods: We included a nationwide cohort diagnosed with EOC from 2005 to 2018. We described age-standardized incidence, surgical patterns, residual disease trends, and cancer-specific survival stratified by age (<70 and ≥ 70 years), stage, and period (2005–09, 2010–13, 2014–18). Results: We included 7522 patients. The incidence decreased from 16.3 (2005) to 11.4 (2018) per 100,000 woman-years, driven by the younger cohort. While the proportion of patients with stage IIIC-IV disease undergoing primary debulking surgery (PDS) decreased, the proportion of patients having interval debulking surgery (IDS) and no debulking surgery increased significantly. In 2014–18, 36% and 24% had PDS for younger and older patients, respectively, compared to 72% and 62% in 2005–09. In both age cohorts, the proportion of patients debulked to no residual disease increased significantly among patients with stage IIIC-IV and in the total cohort. Two-year cancer-specific survival increased from 75% (2005–09) to 84% (2014–18) for younger patients and from 53% to 66% for older patients. After adjusting for potential confounders, age ≥ 70 was associated with a 1.4-fold increased risk of cancer-specific death (95% confidence interval: 1.2,1.5). Conclusions: The proportion of patients with advanced EOC not undergoing PDS or IDS increased significantly. During the same period, patients debulked to no residual disease, and cancer-specific survival increased. However, a survival gap in favor of the younger patients remains after adjusting for potential confounders.
AB - Objective: To examine clinical trends in Denmark for younger and older epithelial ovarian cancer (EOC) patients, focusing on incidence, treatment, and survival changes. Methods: We included a nationwide cohort diagnosed with EOC from 2005 to 2018. We described age-standardized incidence, surgical patterns, residual disease trends, and cancer-specific survival stratified by age (<70 and ≥ 70 years), stage, and period (2005–09, 2010–13, 2014–18). Results: We included 7522 patients. The incidence decreased from 16.3 (2005) to 11.4 (2018) per 100,000 woman-years, driven by the younger cohort. While the proportion of patients with stage IIIC-IV disease undergoing primary debulking surgery (PDS) decreased, the proportion of patients having interval debulking surgery (IDS) and no debulking surgery increased significantly. In 2014–18, 36% and 24% had PDS for younger and older patients, respectively, compared to 72% and 62% in 2005–09. In both age cohorts, the proportion of patients debulked to no residual disease increased significantly among patients with stage IIIC-IV and in the total cohort. Two-year cancer-specific survival increased from 75% (2005–09) to 84% (2014–18) for younger patients and from 53% to 66% for older patients. After adjusting for potential confounders, age ≥ 70 was associated with a 1.4-fold increased risk of cancer-specific death (95% confidence interval: 1.2,1.5). Conclusions: The proportion of patients with advanced EOC not undergoing PDS or IDS increased significantly. During the same period, patients debulked to no residual disease, and cancer-specific survival increased. However, a survival gap in favor of the younger patients remains after adjusting for potential confounders.
KW - Epithelial ovarian cancer
KW - Frailty
KW - Geriatric oncology
KW - Incidence
KW - Interval debulking surgery
KW - Older adults
KW - Primary debulking surgery
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85117951317&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2021.10.081
DO - 10.1016/j.ygyno.2021.10.081
M3 - Journal article
C2 - 34716025
AN - SCOPUS:85117951317
VL - 164
SP - 120
EP - 128
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -